Donaldson Company, Inc. — Q2 FY2023 Form 10-Q
Reporting period: Quarter and six months ended January 31, 2023. Donaldson is a global filtration products and solutions company reporting Mobile Solutions, Industrial Solutions, and Life Sciences segments under a new structure effective November 1, 2022; prior segment results were recast.
Financial performance
| Metric | Three months ended Jan. 31, 2023 | Prior year | Six months ended Jan. 31, 2023 | Prior year |
|---|---|---|---|---|
| Net sales | $828.3 million | $802.5 million | $1,675.6 million | $1,563.4 million |
| Gross margin | 34.3% | 31.1% | 34.1% | 32.4% |
| Operating income / margin | $116.3 million / 14.0% | $95.7 million / 11.9% | $235.6 million / 14.1% | $203.2 million / 13.0% |
| Net earnings | $86.0 million | $71.8 million | $173.2 million | $148.8 million |
| Diluted EPS | $0.70 | $0.57 | $1.40 | $1.18 |
Quarterly sales increased 3.2%, net earnings 19.8%, and diluted EPS 22.0%. Six-month sales rose 7.2%, net earnings 16.4%, and diluted EPS 18.5%. Pricing actions were the main driver of higher gross margins, partly offset by higher input costs. Six-month effective tax rate was 24.7%, versus 25.0% a year earlier.
Segments and sales drivers
- Mobile Solutions: Q2 sales rose 1.7% to $522.5 million; pretax segment earnings were $78.6 million versus $58.6 million. Off-Road growth was partly offset by lower Aftermarket sales as customers reduced inventories.
- Industrial Solutions: Q2 sales rose 12.8% to $246.4 million; pretax segment earnings increased to $46.3 million from $27.2 million. IFS and Aerospace and Defense both grew.
- Life Sciences: Q2 sales declined 15.6% to $59.4 million; pretax segment earnings fell to $6.3 million from $16.7 million. Management cited disk-drive demand weakness and initial negative earnings impact from recent acquisitions, partly offset by food and beverage growth.
For the six months, foreign-currency translation reduced sales by $93.0 million and net earnings by an estimated $11.8 million. U.S. and Canada sales grew, while APAC sales declined year over year.
Cash flow, liquidity, and capital
- Six-month operating cash flow was $220.5 million, versus $79.8 million, primarily reflecting less cash tied up in inventory than in the prior-year period and higher earnings.
- Capital expenditures were $57.6 million, versus $33.5 million. Investing cash outflow was $57.6 million; prior-year outflow included $49.0 million for acquisitions.
- Financing cash outflow was $176.8 million, including $115.2 million of share repurchases and $56.2 million of dividends. Cash declined $13.9 million to $179.4 million.
- Long-term debt was $624.8 million, down from $644.3 million at July 31, 2022; short-term borrowings were $4.0 million. Debt was 34.5% of total capitalization, versus 36.4%. The company reported compliance with debt covenants.
- Donaldson reported $648.0 million of borrowing capacity under existing credit facilities, including $392.5 million available on its $500 million revolving facility. Management said expected operating cash flow, cash, and credit availability should meet requirements for the next 12 months and beyond.
- Working-capital indicators included 64 days sales outstanding (62 at fiscal year-end), 84 days inventory outstanding (78), and 53 days payable outstanding (52).
Outlook, risks, and unusual items
- The filing provides no specific numerical earnings or sales guidance. Management noted inflation in raw materials, labor, and energy continued to pressure margins, although prior pricing actions generally mitigated the impact.
- Fiscal 2023 organizational redesign and related actions generated $16.9 million of charges in the first six months, including $9.3 million in Q2. Q2 charges included $4.8 million mainly related to exiting a lower-margin customer program.
- On February 17, 2023, Donaldson acquired Isolere Bio for $62.5 million; it will be included in Life Sciences. Purchase accounting was not yet final.
- Other disclosed risks include foreign-exchange movements, interest-rate and commodity-price exposure, global demand and geopolitical conditions, supply availability, competition, cybersecurity, and acquisition execution. The company guarantees 50% of certain Advanced Filtration Systems joint-venture debt; the joint venture’s outstanding debt was $64.8 million.
- Recorded claims and litigation liabilities were not material, and management considered material excess settlement costs remote. The company also disclosed $23.0 million of Purilogics contingent consideration liability.
Important facts for investors to verify
- Whether Life Sciences demand and profitability recover from disk-drive weakness and acquisition-related costs.
- Whether pricing continues to offset inflation and whether foreign-exchange pressure persists.
- Whether higher days inventory outstanding and days sales outstanding reverse, and operating cash flow remains strong.
- Progress, purchase accounting, and performance of the Isolere acquisition and other contingent-payment obligations.
- Capital allocation, debt levels, and the potential impact of the AFSI guarantee and other disclosed risks.